Relationship Between Estrogen Receptor Co-regulators and Histological Grade in Estrogen-Dependent Invasive Breast Cancer
American Journal of Clinical and Experimental Medicine
Volume 4, Issue 3, May 2016, Pages: 34-42
Received: Jan. 18, 2016; Accepted: Feb. 9, 2016; Published: Apr. 1, 2016
Views 3180      Downloads 79
Authors
Berti Nelwan, Department of Pathological Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Ilhamjaya Pattelongi, Department of Physiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Muhammad Nasrum Massi, Department of Medical Microbiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Tjakra Manuaba, Deparment of Surgical Oncology, Faculty of Medicine, Udayana University, Denpasar, Indonesia
Cahyono Kaelan, Department of Pathological Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Suryani As’ad, Department of Clinical Nutrition, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Johanna Kandouw, Department of Pathological Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Syarifuddin Wahid, Department of Pathological Anatomy, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Mochammad Hatta, Department of Medical Microbiology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
Article Tools
Follow on us
Abstract
The study aims to assess the relationship between level expression co-regulators of estrogen receptor (SRC1, CBP/p300, NCoR, SMRT) in estrogen-dependent invasive breast cancer with histological grade. The other aims of study to evaluate the interaction between p53, Ki-67, Her-2/Neu expression and co-regulators with the histological grade. Analysis of these relationships will result in deeper understanding on the molecular basis of breast cancer incidence which can be associated with prognosis and prediction of the disease and evaluation of the targeted therapy in breast cancer. The co-regulators and p53, Ki-67, Her-2/Neu were examined using immuno-histochemical technique toward paraffin block of 85 patients with estrogen receptor (ER) α positive. Relationships between these targets and histological grade were analyzed. We observed that SRC1 was associated with a high degree of malignancy and NCoR had a significant correlation with a low degree of malignancy. Interaction of SRC1 and NCoR with p53, Ki-67 and Her-2/Neu is significantly associated with the high degree of malignancy. This study provided evidence that SRC1 and NCoR were the independent prognostic factors. SRC1 was associated with the high grade malignancy (poor differentiation and in the other hand, the NCoR was associated with well differentiation histopathology. High expression of p53, Ki-67 and Her2/Neu which interact with SRC1 and NCoR were associated with a high degree malignancy.
Keywords
ER-α, p53, Ki-67, Her-2/Neu, Histological Grade, Breast Cancer
To cite this article
Berti Nelwan, Ilhamjaya Pattelongi, Muhammad Nasrum Massi, Tjakra Manuaba, Cahyono Kaelan, Suryani As’ad, Johanna Kandouw, Syarifuddin Wahid, Mochammad Hatta, Relationship Between Estrogen Receptor Co-regulators and Histological Grade in Estrogen-Dependent Invasive Breast Cancer, American Journal of Clinical and Experimental Medicine. Vol. 4, No. 3, 2016, pp. 34-42. doi: 10.11648/j.ajcem.20160403.11
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European journal of cancer. 2013; 49(6): 1374-403.
[2]
Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer letters. 2015; 356(2 Pt A): 231-43.
[3]
Campos SM. Aromatase inhibitors for breast cancer in postmenopausal women. The oncologist. 2004; 9(2): 126-36.
[4]
Rosai J.; In: Surgical Pathology. Ackermann. The Breast. 9th ed. St. Lois: Mosby. 2004: 1802-1826.
[5]
Lee AV, Oesterreich S, Davidson NE. MCF-7 cells--changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst. 2015 Mar 31; 107(7).
[6]
Lester S.; In: Robbins and Cottran. Pathologic Basis of Disease. 7th ed. Philadelphia: 2005: 1129-1151.
[7]
Liehr, J. Is Estradiol a Genotoxic Mutagenic Carcinogen? Endocrine Reviews 21 (1): 2000: 40-5.
[8]
Smith L. C; O’Malley W. B. Coregulator Function: A key to understanding tissue specificity of selective receptor modulators. Texas: The Endocrine Society. 2003. 45-63.
[9]
Allred DC, Anderson SJ, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012 Apr 20; 30(12): 1268-73.
[10]
Herynk HM, Fuqua AW, et al. Estrogen Receptors in Resistance to Hormone Therapy. USA: Landes Bioscience and Springer Science. 2007: 131-135.
[11]
Graham DJ, et al; Thoughts on Tamoxifen resistent breast cancer. Are regulators the answer or just a red herring?. Journal of Steroid Biochemistry and Molecular Biology. Colorado. 2000: 1-4.
[12]
Germain, Doris; Estrogen Carcinogenesis in Breast Cancer. New York: Elsevier Inc. 2011; p 473-481.
[13]
Green AR, et al; The Prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. Nottingham: School of Molecular Medical Sciences Nottingham University Hospitals. 2007: 428-436.
[14]
Damjanov I, Fang F.; Cancer Grading Manual; University of Kansas School of Medicine. Kansas City, 2005: 75-80.
[15]
Herynk, MH; Fuqua AW; Suzanne; Estrogen Receptors in Resistance to Hormone Therapy. USA: Landes Bioscience and Springer Science. 2007: 131-135.
[16]
Douglas, Potter, David Yee; Steroid Receptors In Breast Cancer. Philadelphia. 2009: 485-494.
[17]
Ghayad S et al; Prognostic and Predictive Factors in Breast Cancer. 2nd ed. London. 2008: 1008-117.
[18]
Igarashi P.; In: Medical Physiology: Regulation Of Gene Expression. Philadelphia. 2012: 75-105.
[19]
Russo J et al; In: Endocrinology: Adult and Pediatric, 6th ed. Philadelphia. 2010: 2265-2279.
[20]
Nardone, A; De Angelis C; Trivedi, Meghana; Osborne, Kent C; Schiff, Rachel; The Changing Role of ER in Endocrine Resistance, Elsevier Ltd, Orginal Article. 10 Agustus 2015: 560-566.
[21]
Varna M, et al. Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. Br. J. Cancer. 2007 Oct 22; 97(8): 1157-64.
[22]
Busillo JM, et al; Steroid Hormone Action. Yen & Jaffe's Reproductive Endocrinology 7th Edition. Philadelphia. Saunders. 2014: 93-107.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186